Recruiting

CLEOPATTRANNC6019-0001 for Transthyretin Amyloid Cardiomyopathy

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

NNC6019-0001

+ Placebo (NNC6019-0001)

Drug
Who is being recruted

Over 18 Years
+21 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Placebo-ControlledPhase 3
Interventional
Study Start: October 2025
See protocol details

Summary

Principal SponsorNovo Nordisk A/S
Study ContactNovo Nordisk
Last updated: March 20, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: October 2, 2025

Actual date on which the first participant was enrolled.

This study aims to explore whether a new medication called NNC6019-0001 can lower the risk of heart-related death and illness in people with a heart condition known as transthyretin amyloid cardiomyopathy (ATTR-CM). ATTR-CM is a disease that affects the heart's structure and function, leading to serious heart problems. The study is important because it seeks to find better treatment options for those with this condition, potentially improving their quality of life and survival rates. Participants in the study will be randomly assigned to receive either the new medication NNC6019-0001 or a placebo, which is an inactive substance. This ensures that the study results are unbiased and reliable. All participants will continue with their standard heart treatments as advised by their healthcare providers. The study will look at how well NNC6019-0001 works compared to the placebo in reducing heart-related health issues, but no specific outcomes are listed. There are no specific risks or benefits mentioned for participants in this description.

Official TitleCLEOPATTRA: Effects of NNC6019-0001 Versus Placebo on Cardiovascular Outcomes in Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
NCT07207811
Principal SponsorNovo Nordisk A/S
Study ContactNovo Nordisk
Last updated: March 20, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

1280 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Criteria

8 inclusion criteria required to participate
Completed more than 50 meters on the 6MWT at screening.

Age 18 years or above at the time of signing the informed consent.

Male or female.

Have an established diagnosis of ATTR-CM (wild-type ATTR [ATTRwt] or variant ATTR [ATTRv]), with cardiac amyloid infiltration, increased left ventricular (LV) wall thickness, and HF.

Show More Criteria

13 exclusion criteria prevent from participating
Prior solid organ transplant or planned solid organ transplant during the study.

Presence or history of malignant neoplasm (other than basal or squamous cell skin cancer, in situ carcinomas of the cervix, carcinoma in situ/high-grade prostatic intraepithelial neoplasia [PIN], low-risk prostate cancer, or on stable therapy for prostate cancer) within 3 years before screening.

Known or suspected hypersensitivity to study intervention(s) or related products.

Current or previous participation (dosing with active treatment) in a study for an investigational ATTR depleting drug or ATTR gene editing therapy.

Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

2 intervention groups are designated in this study

50% chance of being blinded to the placebo group

Treatment Groups

Group I

Experimental
Participants will receive NNC6019-0001 intravenously (IV). Participants will also have the option to continue any Standard of care (SoC) treatments as recommended by their medical health professional.

Group II

Placebo
Participants will receive placebo matched to NNC6019-0001 IV. Participants will also have the option to continue any SoC treatments as recommended by their medical health professional.

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 285 locations

Recruiting

Hospital Universitario Reina Sofia

Córdoba, SpainOpen Hospital Universitario Reina Sofia in Google Maps
Recruiting

Hospital Universitario Ramon y Cajal

Madrid, Spain
Recruiting

Hospital Universitario La Paz

Madrid, Spain
Recruiting

Hospital Universitario Puerta de Hierro de Majadahonda

Majadahonda, Spain
Recruiting
285 Study Centers